在先进的固体瘤中全面基因组分析的现实世界临床实用性
Yuki Saito1,2, Sara Horie1,2, Yasunori Kogure1
1Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Nature medicine
|January 6, 2026
概括
在晚期癌症患者的综合基因组分析 (CGP) 中,在16.6%的病例中发现了可操作的基因组改变,指导了向治疗. 现实世界的数据显示,CGP在不同类型的瘤中的效用有显著差异,影响了治疗决策.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 精准医学是一门精准的医学.
背景情况:
- 在精密瘤学中,综合基因组分析 (CGP) 是必不可少的.
- 它的实际实用性和对患者结果的影响需要进一步调查.
- 需要进行大规模分析,以了解各种瘤类型的变异.
研究的目的:
- 评估CGP在日本一大批高级固体瘤患者中的实际实用性.
- 评估CGP指导的临床证据级分类的预后价值.
- 为了确定CGP益处的瘤类型之间的差异,并探索瘤不可知生物标志物.
主要方法:
- 分析了来自54,185名接受CGP的高级固体瘤患者的临床和遗传数据.
- 利用一个针对性测序面板,覆盖324个基因.
- 评估了CGP指导的疗法,临床证据水平和预后关联.
主要成果:
- 在16.6%的患者中发现了可预测对已批准疗法的反应的可操作的变化.
- 8%的患者接受了CGP指导治疗,随着时间的推移,情况有所改善.
- 在不同类型的瘤中观察到CGP实用性的显著变化,例如,甲状腺/肺部癌症>20%,胰腺/肝癌<2%.
- 瘤突变负担 (TMB) ≥20个突变/兆基预测了布罗利祖马布在不同瘤类型的治疗结果更好.
结论:
- CGP为个性化癌症治疗提供了有价值的现实世界的见解.
- 根据瘤类型,CGP的临床效用和益处有很大差异.
- 像TMB这样的无瘤生物标志物在指导免疫疗法决策方面表现有前途.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...